Marinus Pharmaceuticals, Inc.

161 articles with Marinus Pharmaceuticals, Inc.

• Marinus Pharmaceuticals Announces New Clinical and Research Data to be Presented at American Epilepsy Society Meeting

  12/3/2021

  Marinus Pharmaceuticals, Inc. today announced new clinical trial and research data being presented at the American Epilepsy Society (AES) Annual Meeting in Chicago, Illinois.

• Marinus Pharmaceuticals Announces Nine Presentations and Virtual Investor Event at American Epilepsy Society 2021 Annual Meeting

  11/22/2021

  Marinus Pharmaceuticals, Inc. today announced that nine abstracts highlighting clinical trial and research data have been accepted for poster presentation at the American Epilepsy Society (AES) Annual Meeting being held in Chicago, Illinois, from December 3 through 7, 2021.

• Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences - Nov 15, 2021

  11/15/2021

  Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, announced that members of its leadership team will present at the following investor conferences in November and December.

• Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2021 Financial Results

  11/9/2021

  Marinus Pharmaceuticals, Inc. today provided an update on its clinical and regulatory development activities and reported its financial results for the third quarter ended September 30, 2021.

• Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Nov 08, 2021

  11/8/2021

  Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced the grant of inducement awards to five new employees.

• Marinus Pharmaceuticals to Provide Business Update and Announce Third Quarter 2021 Financial Results on November 9, 2021

  10/26/2021

  Marinus Pharmaceuticals, Inc. today announced plans to release financial results for the third quarter ended September 30, 2021 before the market opens on November 9, 2021.

• Marinus Pharmaceuticals Joins the Loulou Foundation in Collaboration on CANDID, a Comprehensive Observational Study in CDKL5 Deficiency Disorder

  10/25/2021

  Marinus Pharmaceuticals, Inc . today announced it has joined forces with the Loulou Foundation and six other biotech and pharmaceutical organizations, to undertake a key observational CDD clinical study to better understand the natural history and the utility of various clinical assessments.

• Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 08, 2021

  10/8/2021

  Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced the grant of inducement awards to five new employees.

• Marinus Pharmaceuticals Provides Strategic Update at Virtual R&D Event

  10/5/2021

  Marinus Pharmaceuticals, Inc . will be presenting an overview and update of its pipeline and commercial plans across its programs in CDKL5 deficiency disorder (CDD)

• Marinus Pharmaceuticals Announces Virtual R&D Event on October 5, 2021

  9/28/2021

  Marinus Pharmaceuticals, Inc will host a virtual R&D event for investors and analysts on Tuesday, October 5, 2021, from 9:00 a.m. to 12:00 p.m. Eastern Time.

• Marinus Pharmaceuticals Announces FDA Acceptance for Filing and Priority Review of New Drug Application for Ganaxolone in CDKL5 Deficiency Disorder

  9/20/2021

  Marinus Pharmaceuticals, Inc today announced that the U.S. Food and Drug Administration (FDA) accepted for filing the company’s New Drug Application (NDA) for the use of ganaxolone in the treatment of seizures

• Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 09, 2021

  9/9/2021

  Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced the grant of inducement awards to five new employees.

• European Medicines Agency Grants Marinus Pharmaceuticals Accelerated Assessment of Ganaxolone for Treatment of CDKL5 Deficiency Disorder

  8/26/2021

  Marinus Pharmaceuticals, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted its request for accelerated assessment of its lead product candidate, ganaxolone, for the treatment of seizures associated with CDKL5 deficiency disorder (CDD), a rare, genetic epilepsy.

• Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences - Aug 25, 2021

  8/25/2021

  Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced that members of its leadership team will present at the following investor conferences in September.

• Marinus Pharmaceuticals Reports Topline Ganaxolone Phase 2 Open-Label Results in Tuberous Sclerosis Complex and Receives FDA Orphan Drug Designation

  8/17/2021

  Marinus Pharmaceuticals, Inc. today announced topline data from its open-label Phase 2 trial evaluating safety and efficacy of adjunctive oral ganaxolone treatment in 23 patients with seizures associated with tuberous sclerosis complex (TSC).

• Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results

  8/10/2021

  Anticipate initiating a Phase 3 trial of adjunctive ganaxolone in tuberous sclerosis complex (TSC) in Q3 2021, targeting first patient enrolled during Q4 2021; continue to expect topline Phase 2, open label data in Q3 2021

• Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 06, 2021

  8/6/2021

  Marinus Pharmaceuticals, Inc., a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced the grant of inducement awards to five new employees.

• Marinus Pharmaceuticals Announces Exclusive Collaboration with Orion Corporation for European Commercialization of Ganaxolone

  8/3/2021

  Orion obtains rights to commercialize both the oral and IV franchises of ganaxolone in Europe. Collaboration supports mid-2022 European launch of oral ganaxolone for CDKL5 deficiency disorder, if approved; leverages Orion’s expertise in rare orphan diseases, antiepileptics and European commercialization

• Marinus Pharmaceuticals to Provide Business Update and Announce Second Quarter 2021 Financial Results on August 10, 2021

  8/3/2021

  Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat rare seizure disorders, today announced plans to release financial results for the second quarter ended June 30, 2021 before the market opens on August 10, 2021.

• Marinus Pharmaceuticals Submits New Drug Application (NDA) to FDA for Ganaxolone for the Treatment of Seizures Associated with CDKL5 Deficiency Disorder and Provides Pipeline Update

  8/3/2021

  Marinus Pharmaceuticals, Inc. today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of its lead product candidate ganaxolone, to treat seizures associated with CDKL5 deficiency disorder (CDD), a rare, genetic epilepsy.